| Stage |
Phase |
Principal Investigator |
Study prefix |
Study number |
Title
(click hyperlink for more information) |
| I | I | Nestor Rigual, MD | I | 109307 | Phase I Trial of Photodynamic Therapy with HPPH (2-1[Hexyloxyethyl]-2-Devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and Stage I Carcinoma of the Oral Cavity |
| I | Nestor Rigual, MD | I | 119207 | Phase I Trial of Photodynamic Therapy with HPPH (2-1[hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Larynx |
| II | Todd Demmy, MD | I | 98707 | A Phase II Study of Photodynamic Therapy (PDT) Using 2-[Hexyloxyethyl]-2 Devinyl Pyropheophorbide-A (HPPH) for Treatment of Advanced Obstructing Endobronchial Lung Cancer |
| I | Nestor Rigual, MD | I | 74606 | A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients with Resectable, Primary or Recurrent Head and Neck Cancer |
| Superficial Basal Cell Carcinomas 2-5cm in diameter | Pilot | Nathalie Zeitouni, MD | RP | 00-07 | A Pilot Study of Topical ALA-PDT in Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinomas and Bowen's Disease Investigating the Effects of Decreased Irradiances of Initial PplX Photobleaching Rates and Pain |
| N/A | I | Todd Demmy, MD | I | 05903 | A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for treatment of Bronchogenic Carcinoma in situ or bronchogenic Microinvasive Carcinoma. A Dose Ranging Study |
Print This Page
